sellWeak cluster of 310b5-1 plan
Darlene Noci sold $285k of NUVL
Chief Development Officer at Nuvalent, Inc.. 4,000 shares at an average of $71.31, traded May 29, 2025, filed May 30, 2025.
Warning score
9Value
$285k
4,000 shares
Holdings after
48,034
-8% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +14Trade size$285k at market
- 0Share of holdings soldSold 7.7% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-079770, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 29, 2025 | MOption exercise Class A Common Stock10b5-1 | +2,129 | $14.40 | $31k | 50,163 | May 30, 2025 |
| May 29, 2025 | MOption exercise Class A Common Stock10b5-1 | +1,871 | $27.85 | $52k | 52,034 | May 30, 2025 |
| May 29, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,437 | $71.25 | $245k | 48,597 | May 30, 2025 |
| May 29, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -563 | $71.67 | $40k | 48,034 | May 30, 2025 |
| May 29, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,129 | $0.00 | $0 | 21,259 | May 30, 2025 |
| May 29, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,871 | $0.00 | $0 | 142,329 | May 30, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 17Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 17Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 25Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.2M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $543k 5,500 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.5M 25,130 shares | -23% | |
| 30Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $3.4M 35,104 shares | -35% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.0M 30,000 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $567k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $567k 5,500 shares | -9% | |
| 7Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $561k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.